| |
All
|
No Classical
|
Classical
| |
|---|
|
n = 283
|
n = 87
|
n = 196
|
p-value
|
|---|
|
Age, years
|
66 ± 11
|
67 ± 9
|
65 ± 12
|
0.13
|
|
Women
|
113 (40%)
|
20 (23%)
|
93 (47%)
|
< 0.001
|
|
Days from ECG to CRTa
|
6 (2–25)
|
7 (3–24)
|
6 (1–24)
|
0.89
|
|
Ischemic heart disease
|
136 (48%)
|
55 (63%)
|
81 (41%)
|
< 0.001
|
|
NYHA class III/IV
|
230 (81%)
|
74 (85%)
|
156 (80%)
|
0.32
|
|
QRS duration, ms
|
157 ± 21
|
146 ± 17
|
162 ± 21
|
< 0.001
|
|
QRS duration < 150 ms
|
110 (39%)
|
53 (61%)
|
57 (29%)
|
< 0.001
|
|
Strict LBBB
|
226 (80%)
|
55 (63%)
|
171 (87%)
|
< 0.001
|
|
1st degree AV block
|
51 (18%)
|
16 (18%)
|
35 (18%)
|
0.99
|
|
Atrial fibrillation/flutter
|
82 (29%)
|
30 (34%)
|
52 (27%)
|
0.20
|
|
Hypertension
|
195 (69%)
|
67 (77%)
|
128 (65%)
|
0.05
|
|
Diabetes
|
90 (32%)
|
40 (46%)
|
50 (26%)
|
< 0.001
|
|
Creatinine, mg/dL+
|
1.2 (1.0–1.5)
|
1.3 (1.0–1.6)
|
1.1 (0.9–1.5)
|
0.01
|
|
ACE/ARB
|
230 (81%)
|
68 (78%)
|
162 (83%)
|
0.32
|
|
Betablocker
|
257 (91%)
|
79 (91%)
|
178 (91%)
|
0.82
|
- aMedian (25th–75th percentile), Wilcoxon rank-sum test used for testing differences
- ACE Angiotensin converting enzyme inhibitor, ARB Angiotensin II-receptor blocker, AV Atrioventricular, CRT Cardiac resynchronization therapy, ECG Electrocardiogram; LBBB Left bundle branch block, NYHA New York Heart Association
